Type 2 diabetes: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• GLP-1 66
• SGLT2 40
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• mTOR 0
• NRF2 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• STK11 0
• IL-17 1
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Switzerland· EU contribution €3,885,022· until Dec 2030· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  AI-Powered and Robot-Assisted Opto-Acoustic Evaluation of Systemic Microangiopathy for Ulcer Healing Outcomes in Type 2 Diabetes (ARETEOS)

  Universitatsklinikum Erlangen· Erlangen, Germany· EU contribution €1,499,068· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  First-in-man beta-cell regeneration for causal type 2 diabetes therapy (BetaProtect)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Apr 2028

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Non-invasive Glucose Health Technology (NIGHT)

  DiaMonTech AG· Berlin, Germany· EU contribution €2,499,999· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  STRIKE-T2D: Identifying Causal Microbial Strains Underlying Type 2 Diabetes via Longitudinal Analysis

  Goeteborgs Universitet· Goeteborg, Sweden· EU contribution €236,340· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Modelling endocrine-Immune interactions in response to food Proteins (IMMPRO).

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €194,075· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  BENCHMARKING A ROBUST, HUMAN-RELEVANT PANCREATIC MICROTISSUE PLATFORM FOR METABOLIC DRUG DISCOVERY AND T2D DISEASE MODELING (Pan-NAM)

  Stemx Bio B.v.· Leiden, Netherlands· EU contribution €300,000· until May 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting Cardiovascular Disease with Microbiota-derived Bioactive Compounds (DIETherapy)

  Goeteborgs Universitet· Goeteborg, Sweden· EU contribution €236,340· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 59 running projects, newest first. Listed amounts together: €152.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Suspended

  Effects of DPP-4 Inhibition on Triglycerides

  NCT01527747· Oregon Health and Science University· Updated 7 Apr 2023

  “Funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Source

• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

  NCT05313529· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

  NCT03499704· Celltrion Pharm, Inc.· Source

• Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

  NCT04323189· University of Pennsylvania· Source

• DPP4-Inhibitors and Bone Metabolism in Diabetes

  NCT06770894· Azienda Policlinico Umberto I· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 26
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 113
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 186
• Machine Learning 195
• Deep Learning 32
• Cohort Studies 1111
• Genome-Wide Association Study 315

• Brain connectivity using functional MRI as a potential biomarker of cognitive dysfunction in type 2 diabetes.

  Brain Imaging Behav, Nov 2026

• Magnetic resonance neurography-supported L3-L4 radiculitis presenting as refractory peripatellar neuropathic pain in a patient with diabetes: A case report.

  Medicine (Baltimore), Nov 2026

• Effects and mechanisms of exercise timing on cognitive function in older type 2 diabetes mellitus patients with mild cognitive impairment: A magnetic resonance imaging-based randomized controlled trial protocol.

  PLoS One, Nov 2026

• Hippocampal Subfield Volumes and Spatial Memory Performance in Older Adults At-Risk for Type 2 Diabetes.

  Hippocampus, Nov 2026

• Excess Liver Fat in Type 2 Diabetes Stratified by Intrapancreatic Fat Deposition: A Meta-Analysis of Dual-Organ MRI Studies.

  Liver Int, Nov 2026

• Association between red blood cell count and cortical functional connectivity in type 2 diabetes mellitus patients residing at high altitude: resting-state fMRI study in the Tibetan Plateau.

  Front Endocrinol (Lausanne), Oct 2026

• Multifactorial Contributors to Diagnostic Delay in a High-Risk Patient with Hepatocellular Carcinoma: A Case Report with Clinical Lessons.

  Int Med Case Rep J, Oct 2026

• Regional Adipose Distribution Reveals Differential Genetic Risk Patterns for Cardiometabolic Diseases.

  J Am Heart Assoc, Oct 2026

• Neurovascular uncoupling in type 2 diabetes mellitus: multimodal MRI reveals the association between hippocampal and subcortical structures dysfunction and cognitive decline.

  Front Neurol, Oct 2026

• Disorganized bone collagen fibers in early-stage type 2 diabetes mellitus and its association with adipose tissue redistribution.

  Eur Radiol Exp, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.